Vertex Pharmaceuticals (VRTX) Other Non Operating Income (2009 - 2025)

Vertex Pharmaceuticals' Other Non Operating Income history runs 17 years deep, the most recent figure standing at $6.5 million for Q4 2025.

• On a quarterly basis, Other Non Operating Income rose 143.62% year-over-year to $6.5 million in Q4 2025; TTM through Mar 2026 was $9.9 million, a 113.66% increase from a year earlier, with the FY2025 full-year figure at -$7.7 million, up 91.06% from the prior year.
• Other Non Operating Income improved to $6.5 million in Q4 2025 per VRTX's latest filing, from -$9.8 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $42.4 million in Q3 2021 and bottomed at -$78.1 million in Q2 2022.
• The 5-year median for Other Non Operating Income is -$12.4 million (2023), against an average of -$13.8 million.
• Across the five-year window, Other Non Operating Income plunged 2500.0% in 2024 and jumped 157.14% in 2025, its largest moves.
• Year by year, Other Non Operating Income stood at $7.1 million in 2021, then tumbled by 538.03% to -$31.1 million in 2022, then surged by 68.49% to -$9.8 million in 2023, then slumped by 52.04% to -$14.9 million in 2024, then surged by 143.62% to $6.5 million in 2025.
• Per Business Quant, the three latest VRTX Other Non Operating Income figures stand at $6.5 million (Q4 2025), -$9.8 million (Q3 2025), and $13.2 million (Q2 2025).